Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study

NCT06243432 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT06243432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06243432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Overall status
Unknown status
Start date
February 1, 2023
Completion date
March 1, 2025
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast carcinoma